Welcome to our dedicated page for HEMOGENYX PHARMACEUTICALS news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on HEMOGENYX PHARMACEUTICALS stock.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) is a biopharmaceutical group focused on developing new therapies and treatments for blood diseases. The company's Chimeric Bait Receptor platform shows promise in treating cancers like Non-Hodgkin Lymphoma and solid tumors. Hemogenyx Pharmaceuticals utilizes Artificial Intelligence for protein structure simulations and mRNA synthesis to expedite R&D efforts. With recent FDA consents for Phase I trials of HEMO-CAR-T for AML, the company is advancing towards potentially life-saving treatments.
Rhea-AI Summary
Hemogenyx Pharmaceuticals (HEMO) announces promising results for the potential use of its Chimeric Bait Receptor platform in the treatment of Non-Hodgkin Lymphoma (NHL) and solid tumors. The company's AI-based protein structure simulations and in-house mRNA synthesis have accelerated R&D efforts, showing potential for treating relapsed and/or refractory stage III/IV metastasized NHL and solid tumors like epithelial ovarian cancer and certain carcinomas. Preliminary tests against live infectious SARS-CoV-2 also show promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has successfully completed the re-manufacturing of an improved lentivirus devoid of splice variants, essential for the development of their HEMO-CAR-T cells to treat acute myeloid leukaemia. The re-manufacturing resolves the clinical hold imposed by the FDA, allowing the company to move forward with the IND application and subsequent clinical trials. CEO Dr Vladislav Sandler expressed optimism about the clear path to lifting the clinical hold and the company's commitment to expeditiously resubmit the IND.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc announces that the total issued share capital of the Company consists of 1,153,065,988 ordinary shares. None of the shares are held in treasury. The total number of voting rights in the Company is 1,153,065,988.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals. Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals receives FDA acceptance of plan to address concerns on HEMO-CAR-T IND application
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals announces publication of patent application for chimeric bait receptors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of HEMOGENYX PHARMACEUTICALS (HOPHF)?
The current stock price of HEMOGENYX PHARMACEUTICALS (HOPHF) is $0.04 as of August 5, 2024.
What is the market cap of HEMOGENYX PHARMACEUTICALS (HOPHF)?
The market cap of HEMOGENYX PHARMACEUTICALS (HOPHF) is approximately 20.7M.
What is Hemogenyx Pharmaceuticals focused on?
The company is focused on developing new therapies and treatments for blood diseases.
What is the significance of the Chimeric Bait Receptor platform?
The platform shows promise in treating cancers like Non-Hodgkin Lymphoma and solid tumors.
How does Hemogenyx Pharmaceuticals expedite its R&D efforts?
The company utilizes Artificial Intelligence for protein structure simulations and in-house mRNA synthesis.
What recent FDA development has Hemogenyx Pharmaceuticals achieved?
The FDA has consented to Phase I trials of HEMO-CAR-T for AML, marking progress towards potentially life-saving treatments.
HEMOGENYX PHARMACEUTICALS